Type B - NewAmsterdam Pharma Company N.V. (NAMS) 20261026 Stock Analysis

📅 NewAmsterdam Pharma Key Upcoming Events

• November 09, 2026 Q3 2026 Earnings Release (Estimated)
  • Description: The projected date follows the company’s quarterly reporting cadence and a current financial-calendar estimate. It has not been confirmed by the company and may change. Investors will focus on European commercialization preparation, Menarini-related revenue, operating expenditure, and cash runway.
• December 2026 RUBENS Phase 3 Topline Results (Estimated)
  • Description: NewAmsterdam expects topline results from RUBENS by year-end 2026. The trial evaluates obicetrapib, alone or combined with ezetimibe, in patients with type 2 diabetes or metabolic syndrome requiring additional LDL-C reduction. The precise announcement date remains unconfirmed.
• January–March 2027 PREVAIL Cardiovascular Outcomes Interim Analysis Result (Estimated)
  • Description: Management expects the result of a planned fourth-quarter 2026 interim analysis during the first quarter of 2027. PREVAIL enrolled more than 9,500 patients and evaluates whether obicetrapib reduces major adverse cardiovascular events. The timing is event-driven and may change.

🏢 Step 1: NewAmsterdam Pharma Company Overview & Business Model

Q1-A1. What is NewAmsterdam Pharma?

• Company Name (Ticker): NewAmsterdam Pharma Company N.V. (NAMS)
• Sector: Healthcare
• Exchange: NASDAQ
• Founded: 2019
• Listing Date: November 23, 2022
• Fiscal Year End: December
• Headquarters: Netherlands, Naarden
• CEO: Michael H. Davidson, M.D. (Founder: No)
• Market Cap: $2.36B
• Shares Outstanding: 119.54M
• Current Price: $19.71
• Annual Dividend Yield: ➖ Not applicable
• Ex-dividend Date: ➖ Not applicable
• As-of: October 26, 2026 (ET)

Q1-A2. How Does NewAmsterdam Pharma Make Money?

• Biopharmaceutical Licensing and Commercial Supply: NewAmsterdam develops obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower LDL cholesterol in patients whose existing treatment is insufficient or poorly tolerated. Its monetization model combines development-related payments, commercial supply revenue, potential milestones, and royalties from regional pharmaceutical partnerships.
• European Commercialization Partnership: Menarini holds regional commercialization rights and is responsible for bringing the therapy to patients in its licensed territories. NewAmsterdam retains economic exposure through contractual payments and supply arrangements rather than independently operating every aspect of commercialization.
• Development-Stage Economics: Although the company has achieved its first European regulatory approvals, recurring product-driven revenue remains at an early stage. Most enterprise value reflects expected future commercialization and clinical success rather than existing operating profit.
• Pipeline Optionality: Obicetrapib is being investigated for cardiovascular outcomes, coronary plaque effects, metabolic-risk populations, and preclinical Alzheimer’s disease. These indications represent potential additional markets, not established commercial revenue.

Q1-A3. NewAmsterdam Pharma’s Revenue Segments & Core Income Sources

• Single Reportable Biopharmaceutical Business: NewAmsterdam does not disclose multiple independently operating commercial segments. Reported revenue is associated with its obicetrapib development and partnering activities.
• Commercial Supply Revenue: Second-quarter 2026 revenue was $3.70M, substantially attributable to supply arrangements with Menarini. It accounted for effectively 100% of reported quarterly revenue.
• Development Contributions and Collaboration Payments: Second-quarter 2025 revenue was $19.10M, including $16.10M, or approximately 84.3%, attributable to the second installment of development cost contributions under the Menarini license agreement. This illustrates why historical collaboration revenue cannot be treated as recurring product sales.
• Trailing Revenue: Revenue for the 12 months ended June 2026 was approximately $7.12M, down 88.9% YoY as the prior comparable period included larger development-related payments.
• Future Revenue Drivers: European launches, product supply, contractual milestones, and possible additional market authorizations could diversify revenue over time. The timing and magnitude of these streams remain conditional on partner execution, reimbursement, and regulatory progress.

Q1-A4. Who Are NewAmsterdam Pharma’s Competitors?

• Established LDL-C Therapies: Generic statins and ezetimibe dominate foundational lipid-lowering treatment due to their established clinical efficacy, low cost, and broad accessibility.
• PCSK9 Inhibitors: Amgen’s Repatha and Regeneron’s and Sanofi’s Praluent compete for patients requiring intensive LDL-C lowering, although their injectable administration differs from obicetrapib’s oral approach.
• Other Oral Treatments: Esperion’s Nexletol and Nexlizet compete in the non-statin oral treatment market. Their cardiovascular-outcomes evidence and established commercial access are meaningful competitive factors.
• Emerging Cholesterol Therapies: Inclisiran and other long-acting or investigational lipid-lowering agents compete on efficacy, convenience, safety, and clinical outcomes.
• Strategic Position: NewAmsterdam is neither the first provider of LDL-C treatment nor the dominant established competitor. It is a differentiated entrant attempting to establish an oral CETP inhibitor as an additional treatment option.
• Potential Legacy Displacement: Successful adoption could reduce some incremental prescriptions for injectable treatments or competing non-statin oral therapies, particularly among patients who prioritize oral administration. However, displacement is not inevitable because treatment guidelines, clinical profiles, and patient populations differ.

Q1-A5. What Problem Does NewAmsterdam Pharma Solve?

• Residual Cardiovascular Risk: Many patients remain above recommended LDL-C targets despite statins or other lipid-lowering therapies, creating a need for additional treatment options.
• Convenience and Treatment Burden: A once-daily oral medicine may appeal to patients and clinicians seeking alternatives to injections, provided efficacy, safety, adherence, and access remain competitive.
• Combination Therapy: Combining obicetrapib with ezetimibe in a fixed-dose tablet may simplify multidrug treatment while producing additional LDL-C reduction.
• Clinical Differentiation: Phase 3 studies have demonstrated meaningful LDL-C lowering. However, proving that reductions translate into cardiovascular-event benefits remains especially important for long-term positioning.
• Commercial Constraints: A clinically useful medicine does not automatically capture market share. Payer reimbursement, pricing, physician confidence, guideline adoption, and commercial execution determine actual utilization.

Q1-A6. NewAmsterdam Pharma Key Milestones: Past 12 Months

• December 2025 Initiated the RUBENS Phase 3 Trial
  • Description: The program expanded evaluation of obicetrapib into patients with type 2 diabetes or metabolic syndrome, supporting potential differentiation in cardiometabolic populations.
• January 09, 2026 Outlined 2026 Clinical and Regulatory Priorities
  • Description: Management highlighted preparations for European authorization, ongoing cardiovascular-outcomes development, and approximately $729M in year-end 2025 cash, cash equivalents, and marketable securities.
• March 2026 Completed REMBRANDT Phase 3 Enrollment
  • Description: Enrollment of 323 patients supported evaluation of the obicetrapib-ezetimibe combination’s effects on coronary plaque and related imaging measures.
• May 07, 2026 Q1 2026 Financial Results
  • Description: The company reported $707.30M in cash, cash equivalents, and marketable securities as of March 31, while reaffirming significant clinical and regulatory milestones.
• July 24, 2026 Received Positive CHMP Opinions for Ubeslo and Evlarco
  • Description: The European regulatory committee recommended authorization for obicetrapib monotherapy and the fixed-dose combination with ezetimibe.
• August 05, 2026 Q2 2026 Financial Results
  • Description: The company reported quarterly revenue of $3.70M, net loss of $64.10M, and liquidity of $678.30M. Its planned PREVAIL interim analysis and RUBENS topline milestones remained central development priorities.
• September 21, 2026 European Commission Approved Ubeslo and Evlarco
  • Description: The approvals marked the first regulatory authorization of obicetrapib worldwide, materially reducing European approval risk while shifting attention toward commercial rollout and reimbursement.
• September 29, 2026 First Participant Dosed in the SPINOZA Phase 2b Trial
  • Description: NewAmsterdam advanced investigation of obicetrapib in preclinical Alzheimer’s disease, broadening the molecule’s potential applications without establishing efficacy in that indication.

Q1-A7. Step 1 Key Takeaways

• Step 1 Summary: NewAmsterdam is an emerging cardiovascular biopharmaceutical company transitioning from clinical development toward European commercialization of obicetrapib. The European approvals represent substantial progress, but investment value remains heavily dependent on future cardiovascular-outcomes data, partner commercialization, and sustainable revenue conversion.

🌲 Step 2: NewAmsterdam Pharma’s Economic Moat, Market Size & Scalability

Q2-A1. Does NewAmsterdam Pharma Have a Durable Economic Moat?

• Intellectual Property and Clinical Barriers: Proprietary rights, specialized clinical development capabilities, and Phase 3 evidence create meaningful barriers for direct generic competition during protected periods.
• Regulatory Advantage: European authorizations establish a commercially usable regulatory position that earlier-stage competitors do not possess.
• Clinical Differentiation: Oral administration and combination-tablet convenience offer potential advantages relative to injectable therapies.
• Switching Costs: Treatment switching costs are limited compared with enterprise software or regulated infrastructure. Physicians can prescribe established alternatives when their efficacy, cost, or access profiles are preferable.
• Network Effects: Traditional platform network effects are not relevant. Competitive advantages arise from clinical evidence, patents, regulatory authorizations, and distribution access.
• Pricing Power: The ability to sustain premium pricing is uncertain because inexpensive generic therapies and competing branded drugs constrain reimbursement.
• Moat Durability: The European approvals improve competitive defensibility, but a durable commercial moat requires successful product adoption, favorable postmarketing experience, and clinically differentiated outcomes.

Q2-A2. How Big Is NewAmsterdam Pharma’s Market? (TAM)

• Total Addressable Market: Patients with elevated LDL-C inadequately controlled on standard therapy constitute a substantial population across the United States and Europe. However, the broad cholesterol-treatment market is not equivalent to obicetrapib’s commercially attainable market.
• Market Boundary: The economically relevant opportunity is the incremental non-statin treatment segment, particularly patients who require additional LDL-C lowering or experience limitations with existing therapies.
• Growth Outlook: Demand is supported by cardiovascular disease prevalence, aging populations, intensified preventive treatment, and improved identification of high-risk patients. A defensible single CAGR for the precisely addressable obicetrapib market could not be established.
• Revenue Potential: Even modest market penetration could create revenue substantially above the present collaboration-driven base, but the outcome depends on treatment eligibility, net realized pricing, and partner penetration.
• Market Size Limitation: Applying the entire global cholesterol-treatment market to NewAmsterdam would materially exaggerate achievable revenue and intrinsic value.

Q2-A3. How Real Is NewAmsterdam Pharma’s TAM? (Quality Check)

• Willingness to Pay: Healthcare systems spend substantially on prevention of cardiovascular events, but reimbursement decisions depend on clinical benefit, cost effectiveness, and alternative treatments.
• Competition and Market Structure: Lipid management is a competitive therapeutic category rather than a winner-takes-all market. Several effective therapies already have established prescriber relationships.
• Regulatory Barriers: Pharmaceutical approval requirements, manufacturing standards, and clinical trials limit new entry while creating ongoing compliance costs.
• Commercial Accessibility: European approval permits market entry but does not ensure immediate reimbursement or broad formulary inclusion across countries.
• Market Quality: The patient need is real and medically important, although commercialization economics remain less certain than clinical LDL-C efficacy.

Q2-A4. Can NewAmsterdam Pharma Keep Expanding Its Market?

• Penetration Rate: Commercial penetration remains extremely low because European regulatory authorization is recent and routine product adoption is only beginning.
• Geographic Expansion: Menarini offers an established regional commercialization infrastructure, while additional regulatory filings and approvals could expand accessible markets.
• Indication Expansion: PREVAIL, RUBENS, REMBRANDT, and SPINOZA investigate different clinical opportunities linked to the obicetrapib molecule.
• Operational Scalability: Partner-supported commercialization reduces the need for NewAmsterdam to construct a full sales organization in every territory, although product supply, royalties, and development expenses still require resources.
• Concentration Constraint: Most commercial potential remains tied to one active molecule. Multiple formulations and indications diversify opportunities but do not eliminate molecule-specific risks.

Q2-A5. Step 2 Key Takeaways

• Scoring Rationale:
  • Economic Moat (8/10): Phase 3 evidence, proprietary intellectual property, and European approvals provide meaningful barriers, although pricing power and outcomes differentiation are not yet established.
  • Market Size (5/5): The large population requiring additional LDL-C lowering provides a substantial addressable opportunity across developed healthcare markets.
  • Market Quality·Profitability (6/7): High medical need and an established pharmaceutical reimbursement ecosystem support commercial potential, offset by generic competition and uncertain realized pricing.
  • Market Penetration·Scalability (4/8): Very early penetration offers expansion potential, but dependence on a concentrated pipeline and commercial partners limits proven scalability.
• 📊 Step 2 Score: 23/30 pts (Economic Moat 8/10 + Market Size 5/5 + Market Quality·Profitability 6/7 + Market Penetration·Scalability 4/8)
• Step 2 Summary: NewAmsterdam has a credible regulatory and intellectual-property position in a substantial market, but its commercial moat and scaling economics remain largely unproven.

🚀 Step 3: How Fast Is NewAmsterdam Pharma Growing? Hyper-Growth Metrics

Q3-A1. How Fast Is NewAmsterdam Pharma Growing? (Revenue Trajectory)

• Collaboration Revenue Is Contract-Driven Rather Than a Conventional Growth Curve: FY2024 revenue was $45.56M, falling to $22.50M in FY2025, a 50.6% YoY decline. Trailing revenue declined to $7.12M by June 2026, a further 88.9% YoY decrease.
• Quarterly Revenue Comparison: Q2 2026 revenue was $3.70M, compared with $19.10M in Q2 2025, a decline of approximately 80.6%. The prior-year period included a substantial development contribution that did not repeat.
• Sequential Growth Assessment: The latest comparable quarterly series does not establish sustainable sequential commercial acceleration; the Q2 supply revenue cannot be interpreted as evidence of a recurring product-sales J-curve.
• J-Curve Position: NewAmsterdam is approaching the beginning of potential commercial revenue expansion. The valuation assumes future growth that has not yet appeared consistently in reported revenue.
• Acceleration Verdict: Revenue is currently contracting on a reported basis, while the prospective commercial growth phase remains conditional on European launches and future milestones.

Q3-A2. NewAmsterdam Pharma’s Key Growth Metrics

• Clinical and Commercial Milestone Conversion: Trial progression, regulatory authorization, and partner launch execution are more informative than software-style recurring-revenue metrics because the company is transitioning from drug development to commercialization.
  • Regulatory Conversion: Two European product authorizations were granted in September 2026, representing a significant transition from investigational development toward approved products.
  • Cardiovascular-Outcomes Development: PREVAIL enrolled more than 9,500 patients, establishing a large clinical evidence base for assessing major adverse cardiovascular events.
  • Pipeline Breadth: Phase 3 studies extend into combination therapy, coronary plaque, and metabolic-risk patients, while the SPINOZA Phase 2b study examines a separate Alzheimer’s-related application.
  • Commercial Revenue Conversion: Supply-related quarterly revenue has emerged, but sustained royalty revenue, product uptake, and commercial profitability remain unproven.
• Milestone Quality: Regulatory approval is a realized achievement, whereas future outcomes data and commercial adoption remain probabilistic events.
• Growth Measurement: Pharmaceutical launch prescriptions, reimbursed patient starts, net sales, and royalties will become more valuable operating indicators once the European rollout matures.

Q3-A3. Are NewAmsterdam Pharma’s Unit Economics Improving?

• Gross Margin Interpretation: Reported collaboration and supply revenues are not a reliable proxy for normalized branded-drug gross margins. Revenue recognition does not yet represent a mature and scalable commercial model.
• Operating Cost Burden: Q2 2026 R&D expense reached $41.70M, up from $27.50M one year earlier, reflecting expanding clinical operations.
• Administrative Expense: Q2 2026 SG&A expense was $26.90M, compared with $27.30M one year earlier, suggesting relative control in administrative expenditure.
• Rule of 40: Not economically meaningful during this clinical-to-commercial transition because reported collaboration revenue is episodic and operating cash flow remains negative.
• LTV/CAC: Patient lifetime value and acquisition cost cannot yet be established from public commercial data. These measures are less suitable than net treatment revenue, prescribing penetration, and royalty economics for this pharmaceutical business.
• Unit Economics Conclusion: Potential high-margin pharmaceutical economics have not yet been demonstrated through recurring sales, despite meaningful progress in product approvals.

Q3-A4. Step 3 Key Takeaways

• Scoring Rationale:
  • Revenue Growth Acceleration (3/12): Reported revenue declined sharply as development payments rolled off; a sustained commercial growth curve has not yet developed.
  • Sector-Specific Growth Metrics (8/10): European regulatory authorizations, substantial Phase 3 enrollment, and multiple ongoing clinical programs demonstrate strong development progress.
  • Unit Economics·Margin (2/8): Expenses remain large relative to recurring revenue, and commercial gross-margin economics have not been established.
• 📊 Step 3 Score: 13/30 pts (Revenue Growth Acceleration 3/12 + Sector-Specific Growth Metrics 8/10 + Unit Economics·Margin 2/8)
• Step 3 Summary: Clinical development is progressing considerably faster than reported revenue. Financial acceleration depends on transforming approvals and clinical progress into recurring commercial receipts.

💪 Step 4: NewAmsterdam Pharma’s Profit Potential & Free Cash Flow

Q4-A1. Can NewAmsterdam Pharma Turn Growth Into Profit?

• Operating Loss Trajectory: FY2025 operating loss was approximately $225.68M, compared with $176.29M in FY2024. The trailing operating loss widened to approximately $244.41M by June 2026.
• Quarterly Expense Structure: Q2 2026 R&D and SG&A expenses totaled $68.60M, substantially exceeding quarterly revenue of $3.70M.
• Profitability Distance: A near-term operating break-even point is not supported by current recurring revenue. Meaningful commercialization expansion or substantial contractual receipts would be needed before operating expenses could be covered.
• Potential Leverage: Partner-led commercialization could improve operating leverage if royalties and supply profits expand without proportional growth in NewAmsterdam’s internal commercial expenses.
• Profitability Outlook: The company has a plausible longer-term route toward profitability, but current figures do not establish a credible break-even date within the next two years.

Q4-A2. Does NewAmsterdam Pharma Generate Free Cash Flow?

• Operating Cash Flow: Cash used in operations during the first six months of 2026 was $69.82M, compared with $74.14M during the first half of 2025.
• Free Cash Flow: With capital expenditure of approximately $0.12M, first-half 2026 FCF was approximately -$69.94M.
• Trailing Cash Generation: TTM FCF through June 2026 was approximately -$143.72M, compared with -$148.03M during FY2025.
• Cash Runway: June 2026 liquidity of $678.30M represented approximately 4.7 years of runway at the latest TTM FCF burn rate, before changes in commercialization investment, working capital, and financing.
• Capital Efficiency: The asset-light development model limits physical capital expenditure, but substantial ongoing clinical and personnel expenses prevent self-funding.
• Liquidity Assessment: The company has significant financing flexibility and does not appear to face immediate capital exhaustion. Future commercial expansion and clinical programs could materially alter the present burn-rate calculation.

Q4-A3. Step 4 Key Takeaways

• Scoring Rationale:
  • Operating Leverage·Path to Profit (3/8): SG&A stability provides some cost discipline, but widening operating losses and limited recurring revenue leave profitability distant.
  • FCF·Capital Efficiency (2/7): Cash burn remains significant, although strong liquidity and limited physical capital expenditure reduce near-term funding pressure.
• 📊 Step 4 Score: 5/15 pts (Operating Leverage·Path to Profit 3/8 + FCF·Capital Efficiency 2/7)
• Step 4 Summary: NewAmsterdam possesses substantial liquidity but has not demonstrated operating leverage or positive free cash flow. Clinical and commercial investment continues to consume cash.

👔 Step 5: NewAmsterdam Pharma Management & Shareholder Alignment

Q5-A1. Who Leads NewAmsterdam Pharma? (Founder & Management)

• Executive Leadership: Michael H. Davidson, M.D., serves as Chief Executive Officer and brings extensive experience in cardiovascular medicine, lipid management, and pharmaceutical development.
• Founder Status: Davidson is not identified as the company’s original founder, although he has been central to its public-market leadership and clinical strategy.
• Scientific Leadership: Chief Scientific Officer Johannes Jacob Pieter Kastelein contributes specialist expertise in lipid-related drug development.
• Strategic Vision: Management is pursuing a differentiated oral, non-statin therapy portfolio aimed at reducing residual cardiovascular risk.
• Execution Record: Completion of major Phase 3 development programs, the European regulatory approvals, and further trial launches demonstrate execution against important development milestones.
• Guidance Reliability: The company has delivered several previously discussed clinical and regulatory objectives. However, a consistent record of achieving commercial sales or profitability forecasts does not yet exist.
• Management Assessment: Clinical credibility is comparatively strong, while commercialization remains the next major test of management effectiveness.

Q5-A2. Is NewAmsterdam Pharma’s Management Aligned With Shareholders?

• Executive Ownership: Insider ownership was approximately 0.89%, indicating that management economic exposure is relatively limited compared with the company’s institutional shareholder base.
• CEO Open-Market Purchase: Davidson purchased 10,000 shares on September 14, 2026, at $22.65 per share, representing approximately $226,500 of personal investment.
• Chief Scientific Officer Sales: Kastelein sold approximately 125,000 shares on August 24, 2026, at approximately $26.91 and 50,246 shares on September 30, 2026, at approximately $25.03. The latter transaction was reported under a prearranged trading plan.
• Earlier Executive Sales: Davidson reported sales of approximately 165,408 shares on February 26 and 443,707 shares on March 2, 2026, totaling more than $20M in reported transaction value.
• Net Insider Flow: Identified open-market purchases and sales over the trailing year were substantially net negative, approximately $61.77M, although this includes transactions with potentially different planning and liquidity motivations. The CEO’s later personal purchase is a positive counter-signal but does not offset the aggregate scale of sales.
• Equity Compensation: Share-based compensation totaled approximately $36.38M for the first six months of 2026. Equity incentives can support retention of scientific personnel but also transfer value from existing shareholders through dilution.
• Governance Assessment: Management has operational expertise and meaningful performance incentives, but low aggregate insider ownership, substantial insider sales, and ongoing equity issuance moderate the strength of shareholder alignment.

Q5-A3. Step 5 Key Takeaways

• Scoring Rationale:
  • Founder Management·Vision (7/8): Experienced cardiovascular leadership and successful major development milestones support high management credibility despite the absence of founder-CEO continuity.
  • Alignment·Accountability (3/7): A recent CEO purchase supports confidence, but aggregate insider selling, modest insider ownership, and material equity compensation weaken alignment.
• 📊 Step 5 Score: 10/15 pts (Founder Management·Vision 7/8 + Alignment·Accountability 3/7)
• Step 5 Summary: Experienced leadership has executed important clinical milestones, but shareholder alignment is mixed because substantial share-based compensation and insider sales offset some positive management signals.

⛵ Step 6: NewAmsterdam Pharma Market Flow & Sentiment

Q6-A1. Analyst Consensus vs NewAmsterdam Pharma Guidance

• Revenue Expectations: Compiled FY2026 revenue consensus was approximately $29.29M, compared with FY2025 revenue of $22.50M. The projected increase largely depends on timing-sensitive commercial and contractual receipts.
• Earnings Expectations: FY2026 consensus adjusted EPS was approximately -$1.96, while the estimated annual operating loss was $258.60M.
• Guidance Comparison: Management has emphasized clinical milestones and cash sufficiency rather than providing directly comparable full-year product-sales and EPS guidance. A numerical guidance-versus-consensus midpoint gap therefore cannot be reliably calculated.
• Analyst Sentiment: The compiled average 12-month analyst price target was approximately $49.96 across 16 covering analysts, substantially above the current share price. This is an external aggregate expectation, not an independently established intrinsic value.
• Expectation Risk: Bullish analyst positioning may reflect high confidence in obicetrapib’s long-term potential, but near-term revenue and cash flow remain weak. The company is sensitive to clinical-event outcomes and commercialization assumptions.

Q6-A2. What Is NewAmsterdam Pharma’s Short Interest?

• Institutional Ownership: Approximately 75.16% of outstanding shares were institutionally held, reflecting substantial professional-investor participation.
• Short Interest: Reported short interest was approximately 19.05M shares, compared with 15.66M in the preceding measurement.
• Short Position Concentration: Short positions represented approximately 18.64% of the provider’s stated outstanding-share reference base. A consistently defined percentage of free float could not be established from the retrieved dataset.
• Days to Cover: The reported short ratio was approximately 10.36 trading days, signaling a potentially meaningful supply-demand imbalance during unexpected positive or negative developments.
• Market Interpretation: High short interest can amplify gains on favorable clinical announcements, but it also suggests substantial disagreement about the company’s commercial prospects and valuation.
• Sentiment Conclusion: Institutional sponsorship is significant, yet elevated and rising short positioning signals persistent investor skepticism.

Q6-A3. Step 6 Key Takeaways

• Scoring Rationale:
  • Consensus vs Guidance (2/3): Positive analyst expectations and development milestones support sentiment, although directly comparable commercial guidance is unavailable.
  • Supply·Short Interest (1/2): Institutional participation is strong, but elevated short interest increases volatility and indicates divided conviction.
• 📊 Step 6 Score: 3/5 pts (Consensus vs Guidance 2/3 + Supply·Short Interest 1/2)
• Step 6 Summary: Market expectations remain optimistic about the long-term drug opportunity, while elevated short interest and the absence of established commercial earnings create substantial event-driven volatility.

🧨 Step 7: NewAmsterdam Pharma Catalysts & Price Triggers

Q7-A1. What Could Re-Rate NewAmsterdam Pharma Stock? (Next 12 Months)

• 1 PREVAIL Cardiovascular-Outcomes Trial
  • Timing: Interim-analysis result expected in Q1 2027.
  • Success Conditions: Favorable cardiovascular-event findings would strengthen obicetrapib’s differentiation and potentially support regulatory and commercial opportunities.
  • Failure Risk: Unfavorable outcomes or inconclusive interim evidence could weaken the investment thesis even if LDL-C reduction remains clinically established.
• 2 European Commercialization of Ubeslo and Evlarco
  • Timing: Commercial rollout and early market-access developments through 2027.
  • Success Conditions: Menarini secures reimbursement, physician adoption, and meaningful patient prescriptions, allowing royalties and product supply revenue to develop.
  • Failure Risk: Reimbursement delays, generic competition, and slow physician adoption restrict revenue conversion.
• 3 RUBENS Phase 3 Readout
  • Timing: Topline results expected by year-end 2026.
  • Success Conditions: Favorable efficacy and safety data support obicetrapib’s clinical applicability in patients with metabolic syndrome or type 2 diabetes.
  • Failure Risk: Disappointing efficacy or tolerability reduces confidence in broader positioning.

Q7-A2. NewAmsterdam Pharma’s Estimate Revision Trend

• Revenue Forecast: Compiled FY2026 revenue expectations of approximately $29.29M imply growth relative to FY2025, but milestone timing can produce large estimate changes without corresponding changes in underlying patient demand.
• Earnings Forecast: FY2026 adjusted EPS is expected to remain negative at approximately -$1.96.
• Revision Evidence: A comparable sequence of consensus snapshots covering the latest 90 days was not established. The current estimates therefore do not demonstrate a verified upward revision trend.
• Forward Interpretation: Early European launch data and forthcoming clinical milestones are likely to influence estimates more materially than small near-term changes in recognized collaboration revenue.

Q7-A3. Step 7 Key Takeaways

• Scoring Rationale:
  • Catalyst Strength (3/3): PREVAIL, RUBENS, and the European commercial rollout provide several credible and potentially material catalysts.
  • Estimated Trend (1/2): Revenue expectations imply a future increase, but a sustained upward consensus revision trend is not established.
• 📊 Step 7 Score: 4/5 pts (Catalyst Strength 3/3 + Estimated Trend 1/2)
• Step 7 Summary: NewAmsterdam faces a catalyst-rich period centered on cardiovascular outcomes and initial European commercialization, while financial estimate momentum remains insufficiently established.

⚖️ Step 8: Is NewAmsterdam Pharma Fairly Valued? Valuation Analysis

Q8-A1. NewAmsterdam Pharma’s Key Valuation Multiples

• PS Ratio: 330.86x (very overvalued) — the trailing revenue denominator is small and affected by collaboration-payment timing.
• P/FCF Ratio: N/A (not applicable) — free cash flow is negative.
• P/OCF Ratio: N/A (not applicable) — operating cash flow is negative.
• EV/Sales Ratio: 235.63x (very overvalued) — enterprise value remains large relative to current reported revenue.
• EV/EBITDA Ratio: N/A (not applicable) — EBITDA is negative.
• EV/FCF Ratio: N/A (not applicable) — free cash flow is negative.
• Forward PE: N/A (not applicable) — expected earnings remain negative.
• PEG Ratio: N/A (not applicable) — there is no meaningful positive earnings-growth base.
• Scoring Rationale: The company’s valuation is supported primarily by anticipated drug commercialization and future outcomes evidence, not current sales or profitability. Conventional sales multiples appear exceptionally high, although their usefulness is limited by episodic licensing revenue.
• 📌 (1) Axis Q8-A1 Score: -4

Q8-A2. NewAmsterdam Pharma vs Peers: Valuation Comparison

• Multiple selection based on peer comparison: EV/Sales is a possible comparative metric for loss-making developers, but meaningful peer comparability requires similar licensing revenue definitions, clinical stages, commercial rights, and anticipated royalty economics. Companies with mature marketed products or different partnership structures are not directly comparable.
• Calculation of peer-to-peer deviation rate: A defensible numerical deviation cannot be established because a consistent current peer group with comparable recurring revenue definitions and operating stages was not available.
  • 🧮 Calculation Formula: ((NewAmsterdam EV/Sales 235.63x - comparable peer mean unavailable) / comparable peer mean unavailable) × 100 = not calculable.
• Scoring Rationale: A simple average of unrelated biotechnology revenue multiples would assign misleading economic meaning to development milestones and one-off licensing receipts. The peer comparison is unscored rather than treated as evidence of fair valuation.
• 📌 (2) Axis Q8-A2 Score: 0

Q8-A3. What Is NewAmsterdam Pharma Worth in the Future? (Forward Valuation)

• Implied Future Multiple: An adequately supported 2028–2029 forward earnings or recurring-commercial-revenue multiple cannot be established. NewAmsterdam is entering commercialization, but dependable product-level net sales, royalty receipts, and associated funding requirements are not yet observable.
• Scoring Rationale: Forecasting a mature recurring revenue base from present contractual receipts would require substantial assumptions about pricing, payer access, market share, partner royalties, and clinical outcomes. A future-date multiple with defensible discounting and dilution adjustments therefore cannot be calculated reliably.
• 📌 (3) Axis Q8-A3 Score: ➖

Q8-A3-1. What Growth Hurdle Does the Market Demand From NewAmsterdam Pharma? (Forward Valuation Alternative)

• Scoring Rationale: With a market capitalization of approximately $2.36B, only $7.12M of trailing revenue, and negative free cash flow, the share price depends on substantial commercialization growth. European approval reduces clinical-regulatory uncertainty, but strong prescription uptake, reimbursement, and favorable cardiovascular outcomes remain necessary to justify the current equity value. The growth hurdle is demanding rather than supported by established financial performance.
• 📌 (3) Axis Q8-A3-1 Score: -3

Q8-A4. Final Valuation Adjustment

• Scoring Rationale: The September 2026 European approval represents a significant positive development, but the approval’s expected commercialization value is already central to the valuation assessment. The cash balance supports financing flexibility but is incorporated in enterprise-value measures rather than treated as an additional independent valuation benefit.
• 📌 (4) Axis Q8-A4 Score: 0

Q8-A5. Valuation Adjustment Score Calculation

• Calculation Process:
  • (1) Axis (Key Valuation Indicator): -4 pts (Very Overvalued)
  • (2) Axis (Peer-to-peer deviation rate): 0 pts (Comparable peer deviation unavailable)
  • (3) Axis (Justification of Growth): -3 pts (Commercial growth hurdle remains demanding)
  • (4) Axis (Final adjustment): 0 pts (No independent adjustment)
• 📊 Valuation Adjustment Score: A1 (-4) + A2 (0) + A3 (-3) + A4 (0) = -7 pts
• Commentary: The valuation is difficult to justify using current financial performance. Although the first European approvals reduce regulatory risk, substantial future commercialization success is necessary to support the market capitalization.
• Step 8 Summary: NewAmsterdam offers meaningful clinical and commercialization optionality, but the current valuation carries considerable expectations for growth that has not yet been demonstrated through recurring product revenue.

💀 Step 9: What Are the Risks of NewAmsterdam Pharma? Fatal Risks & Pre-Mortem

Q9-A1. Is NewAmsterdam Pharma Burning Cash & Diluting Shareholders?

• Cash Consumption: Trailing free cash flow was approximately -$143.72M, reflecting substantial clinical spending and limited recurring revenue.
• Liquidity: The June 2026 cash, cash equivalents, and marketable securities balance was $678.30M, providing material liquidity coverage relative to the observed annual burn rate.
• Share Count Expansion: Shares outstanding increased approximately 12.87% YoY to 119.54M, indicating dilution materially above ordinary low-single-digit issuance levels.
• Equity Compensation: First-half 2026 share-based compensation was approximately $36.38M, creating continuing shareholder dilution pressure.
• Funding Outlook: Immediate financing distress is not indicated by the latest reported liquidity. However, persistent losses and expanding clinical or commercial programs could increase future capital requirements.
• Shareholder Risk: Even with sufficient corporate cash, continued equity issuance can reduce each existing shareholder’s proportional ownership of future obicetrapib economics.

Q9-A2. Do Competition or Regulation Threaten NewAmsterdam Pharma?

• Competitive Threat: Generic statins and ezetimibe, injectable PCSK9 therapies, and competing oral products offer alternative treatment strategies with established clinical and commercial histories.
• Clinical Outcomes Risk: LDL-C lowering is important, but favorable cardiovascular-outcomes evidence would materially strengthen differentiation. Failure to demonstrate the expected clinical benefit could reduce the therapy’s long-term commercial potential.
• Regulatory Risk: European approval has removed an important initial authorization barrier, but other jurisdictions remain subject to separate regulatory requirements and decisions.
• Reimbursement Risk: Payers may restrict access or require prior authorization, step therapy, or unfavorable net pricing.
• Commercial Execution Risk: Dependence on Menarini creates exposure to the partner’s launch priorities, field-force execution, and local market-access negotiations.

Q9-A3. NewAmsterdam Pharma Pre-Mortem: What Could Go Wrong?

• 1 PREVAIL results weaken the clinical differentiation thesis: If cardiovascular outcomes are unfavorable or materially less compelling than expected, investors could substantially reduce anticipated long-term revenue and market-share assumptions.
  • Early Warning Signal: Official PREVAIL communications indicate unfavorable efficacy, safety concerns, or an adverse development trajectory.
• 2 European commercialization fails to achieve meaningful prescription adoption: Obicetrapib could remain a niche therapy if reimbursement barriers, competitive pressure, or limited physician uptake restrict prescribing.
  • Early Warning Signal: Successive reporting periods show limited royalty and supply revenue despite expanded commercial availability.
• 3 Persistent cash consumption and dilution reduce per-share value: If commercial revenue develops more slowly than operating expenditure, new equity issuance could finance additional investment at unfavorable shareholder economics.
  • Early Warning Signal: Annualized cash burn accelerates while the share count continues growing materially faster than clinical commercialization progress.

Q9-A4. Risk Adjustment Score

• Reason for Scoring: NewAmsterdam’s 12.87% YoY share-count increase represents material realized dilution, while $36.38M of first-half share-based compensation and ongoing negative cash flow create a continuing risk to per-share ownership economics. However, the $678.30M liquidity balance substantially mitigates near-term solvency risk. Clinical outcomes and reimbursement uncertainty add execution exposure without establishing a current regulatory failure.
• 📊 Risk Adjustment Score: -7 pts
• Step 9 Summary: Significant dilution and continuing cash consumption are the most concrete financial risks. Strong liquidity reduces immediate survival pressure, but clinical and commercial execution remain decisive for long-term shareholder value.

🎯 Step 10: NewAmsterdam Pharma Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

• Investment Score Calculation Formula:
  • Step breakdown: S2 (23) + S3 (13) + S4 (5) + S5 (10) + S6 (3) + S7 (4) = 58 pts
  • Steps 2-7 Sum (58 pts) + Valuation Adjustment (-7 pts) + Risk Adjustment (-7 pts) = Investment Score 44 pts
• Investment Score & Rating: 44 pts (F Rating ⛔)
  • Commentary: Strong intellectual-property positioning, successful European authorization, and a meaningful cardiovascular-development pipeline support the underlying business opportunity. However, contracting reported revenue, substantial operating losses, shareholder dilution, and demanding commercialization expectations materially weaken the current investment profile.

Q10-A2. Should You Buy NewAmsterdam Pharma? (Recommendation)

• Recommendation: Avoid
  • Commentary: NewAmsterdam has achieved genuine scientific and regulatory progress, but the current equity investment depends heavily on favorable future clinical evidence and successful commercial adoption. Weak recurring revenue, persistent losses, and material dilution make the risk-reward profile insufficiently established despite a substantial cash balance.

Q10-A3. Investment Thesis in One Line

• NewAmsterdam Pharma’s European approvals and cardiovascular pipeline create significant commercial potential, but unproven recurring revenue, substantial dilution, and dependence on PREVAIL outcomes make its investment case highly speculative.

Q10-A4. NewAmsterdam Pharma’s Price Trend & Key Drivers

• Stock Price Trend Over the Past 12 Months: Declining 📉 — Shares fell approximately 44.8% over the preceding year, closing at $19.71 on October 23, 2026. The stock also declined approximately 43.8% YTD, with a 52-week trading range of $19.13–$42.21.
• September 2026 European Commission Approvals of Ubeslo and Evlarco
  • Description: European marketing authorization represented the first global regulatory approval of obicetrapib and removed an important barrier to commercial introduction.
  • Stock Price Reaction: Continued Weakness 📉 — Although the approval was strategically favorable, shares remained under pressure across the subsequent late-September and October trading period. The broader decline cannot be attributed solely to the approval announcement.
• October 23, 2026 Sharp Share-Price Decline
  • Description: The stock ended the session at $19.71, down from $21.58 on October 22, with trading volume of approximately 2.31M shares.
  • Stock Price Reaction: Sharp Decline 📉 — Shares fell 8.67% during the October 23 session, reaching an intraday low of $19.13. The immediate cause was not conclusively established.

Q10-A5. Action Plan

• ⚠️ Since the Investment Score for the analyzed company is 44 pts and the Recommendation falls under Avoid, this Action Plan section is omitted as the stock is not suitable for investment.

🕵️‍♂️ Deep Dive Analysis

• ⚠️ Since the Investment Score for the analyzed company is 44 pts and the Recommendation falls under Avoid, this Deep Dive section is omitted as the stock is not suitable for investment.